BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Spectros Sales Revenue Up 69% in 2011


2/7/2012 10:19:49 AM

PORTOLA VALLEY, Calif., Feb. 7, 2012 /PRNewswire/ --Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.

"This accelerating growth continues to send a strong signal that the market is embracing the Spectros broadband tissue oximetry," notes CFO John Bagnatori.

Spectros T-Stat® is the only broadband tissue oximeter on the market in the U.S., Europe, and Asia. T-Stat's proprietary broadband oximetry relies on over 260 wavelengths of light, compared just 2-4 wavelengths used in other oximeters. T-Stat competes with INVOS® oximeters marketed by Covidien, and FORE-SIGHT® oximeters marketed by CAS Medical. In reconstructive surgery, T-Stat competes with oximeters marketed by ViOptix.

An expanded array of products, including broadband infrared Ceres cerebral probes and multi-site T-Stat monitors are under development.

About Spectros

Spectros markets advanced molecular devices that shed light on ischemia and cancer. Spectros is also developing molecular imaging contrast agents for surgical guidance during breast and prostate cancer surgeries, currently undergoing phase I/II clinical trials. Spectros is a venture-supported concern.

(Note: Forward-looking statements do not constitute an offer for investment nor a guarantee of future events or returns. Certain applications described above have not been reviewed by the FDA, and are therefore labeled for investigational use only. T-Stat is a trademark of Spectros. INVOS is a trademark of Somanetics and Covidien). FORE-SIGHT is a trademark of CAS Medical.

For further information, visit www.spectros.com.

Web Site: http://www.spectros.com

SOURCE Spectros



Read at BioSpace.com

Spectros
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES